Juul Labs CEO Announces Company's Next Steps

Oct.09.2022
Juul Labs CEO Announces Company's Next Steps
Juul CEO announces cancellation of overseas expansion plans, debt refinancing, and potential bankruptcy as the company fights for survival.

Recently, the CEO of Juul Labs Inc., KC Crosthwaite, announced that the company is canceling its plans for international expansion. They have also undergone a refinancing process for some of their debts and are currently struggling to keep the business afloat.


The board of directors, leadership team, and I are continuing to evaluate all options to ensure that we take the necessary steps to help us fight for our mission - a battle that has been going on for many years," said CEO KC Crosthwaite in a statement.


In the ongoing dispute with the U.S. Food and Drug Administration (FDA) over whether its e-cigarettes can remain on the U.S. market, Juul has been preparing to file for bankruptcy protection. Crosthwaite stated that the company is still considering various restructuring plans, including bankruptcy, but has not made any decisions yet.


Crosthwaite announced that the company will be laying off some employees after cancelling its plans to expand outside of the United States. He also stated that Juul has successfully refinanced its debt to allow for more time to explore longer-term options.


We firmly believe that we have a future in which millions of adult smokers around the world will be able to use Juul products," said Crosthwaite. "To make this future a reality, we must continue to fight and make difficult decisions.


In 2018, Juul disrupted the tobacco market when its stylish flash-drive shaped vaporizer drove a surge in electronic cigarette use in the United States. Since then, Juul has faced lawsuits and regulatory crackdowns. The company has attempted to repair its image by appointing a new CEO in 2019 and voluntarily discontinuing the sale of fruit flavors in the US, as well as ceasing most of its marketing activities in the country.


Juul Labs CEO KC Crosthwaite has announced that the company will be laying off employees following a decision to withdraw plans for international expansion. Juul, which had approximately 3,000 employees in 2019, has already cut two-thirds of its workforce due to declining sales and increased losses. The company currently employs around 1,200 workers, including approximately 100 outside of the US, and the impact of the latest layoff decisions on their positions is unclear at this time.


The company Juul had previously planned to expand distribution in Canada, with their latest device JUUL2 launching earlier this year and being sold online and in around three dozen stores in Toronto. Juul also plans to re-establish employees in Italy and Switzerland, where their original e-cigarettes are currently sold through local distributors.


In 2020, due to a voluntary decision to reduce marketing efforts and cease sales of their sweet and fruity flavors in the United States, the company withdrew from most international markets as a result of declining revenue. In June, the FDA ordered Juul to remove their e-cigarettes from the U.S. market, stating insufficient proof of safety. The agency subsequently suspended the order pending Juul's appeal. However, sources reveal that Juul's sales in the U.S. continued to decline, prompting the company to abandon their overseas plans.


Juul faces thousands of lawsuits accusing the company of selling its products to children. Some of these lawsuits are scheduled to go to trial next year. Disputes with the FDA have hindered Juul's ability to raise funds or obtain traditional bank loans to pay for legal settlements or court judgments.


Since last year, Juul has agreed to pay over $525 million in settlements to several states that have been investigating or taking legal action against the company. There are still pending cases, including lawsuits filed by nine other attorneys general. The company maintains that it has never targeted underage users.


According to a federal investigation released on Thursday, Juul did not make it to the list of the most popular e-cigarette brands used by high school students.


Statement:


This article is compiled based on third-party information and is intended for industry communication and learning purposes only.


This article does not represent the views of 2FIRSTS, and 2FIRSTS is unable to confirm the authenticity and accuracy of the article's content. The compilation of this article is only intended for industry-related communication and research.


Due to limitations in our translation capabilities, the translated article may not fully express the same meaning as the original. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government in regards to any domestic, Hong Kong, Macao, Taiwan, or foreign-related statements and positions.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Philip Morris Japan (PMJ) launched Bold Ruby as a new regular color for the IQOS ILUMA i and IQOS ILUMA i ONE in Japan on September 16, 2026, priced at JPY 6,980 and JPY 3,980, respectively. Initial sales began through IQOS online and physical channels, with convenience stores and selected tobacco retailers set to follow from September 29. Bold Ruby is a regular rather than limited-edition colorway and is available for the ILUMA i and ILUMA i ONE, but not the ILUMA i PRIME. The release does not involve changes to the devices' core hardware or functions.
Sep.22
Elf Bar Vape Explosion and Amputation Claim Spurs Coverage Suit, U.S. Insurer MUSIC Seeks Ruling It Owes No Duty to Defend or Indemnify Distributor i5
Elf Bar Vape Explosion and Amputation Claim Spurs Coverage Suit, U.S. Insurer MUSIC Seeks Ruling It Owes No Duty to Defend or Indemnify Distributor i5
Mesa Underwriters Specialty Insurance Company has asked a federal court in Washington to declare that it has no duty to defend or indemnify vape distributor i5 Distribution in a product liability case involving an Elf Bar BC5000. The plaintiff alleges that the disposable vape caught fire and exploded in his pocket, causing severe burns and ultimately requiring an above-the-knee amputation of his left leg. MUSIC is relying on a tobacco, nicotine or nicotine replacement products exclusion and a premises limitation endorsement. The court has not ruled on the coverage dispute.
News
Sep.10
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia’s Department of Home Affairs has hired Deloitte to provide data analytics, business-process, communications and project-delivery support to the Office of the Illicit Tobacco and E-Cigarette Commissioner. The government says Deloitte personnel do not provide policy advice to the Commissioner or the Australian government, with policy development and decision-making remaining with public officials. The arrangement has nevertheless drawn scrutiny because Deloitte has previously provided professional services to several tobacco and vaping companies.
Sep.03
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
U.S. Smokeless Tobacco Company, an Altria Group company, has broken ground on an approximately $250 million manufacturing expansion in Hopkinsville, Kentucky. The roughly 270,000-square-foot facility is expected to create more than 200 jobs and absorb processing, manufacturing and packaging operations currently split between Hopkinsville and Nashville, Tennessee. USSTC previously said production at its Nashville facility is expected to wind down by early 2028. The project forms part of Altria’s broader effort to modernize and consolidate its U.S. smokeless tobacco manufacturing network.
Sep.10
Switzerland Tightens Vape Checks as Only 3 of 32 Tested Products Meet New Tobacco Rules
Switzerland Tightens Vape Checks as Only 3 of 32 Tested Products Meet New Tobacco Rules
According to Swiss media outlet Blick, local authorities are strengthening compliance checks on vape products, nicotine pouches and other tobacco-related products following the implementation of Switzerland’s revised Tobacco Products Act. A Basel laboratory tested 32 disposable vapes and e-liquids, with only three meeting regulatory requirements and 21 products banned from sale. Swiss authorities are also expanding retail inspections, laboratory testing and youth purchase checks to enforce the new tobacco and nicotine product rules.
Aug.12
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22